BLINKLAB LIMITED (ASX: BB1)
Health care · News and insights
Price unavailable
Latest BB1 announcements
Announcement Insights
BlinkLab Reports Early SHANK2 Findings as Dx1 FDA Study Remains on Track
BlinkLab’s research programme has delivered an early SHANK2 autism study readout, while its pivotal FDA study for Dx1 remains on track. On 11 November, the company reported statistically significant differences in several measured responses in a small SHANK2-related autism group, ahead of the previously expected Q1 2027 timing; the exploratory results do not change the Dx1 programme. In October, BlinkLab said its European ADHD study supported Dx2 development but was insufficient for regulatory submission, and that further research readouts were expected.
Updated 11 Nov 2026, 09:27 AM Sydney time
Sources
Positive Results in Genetic Autism Study Ahead of ScheduleTrading HaltQuarterly Activities/Appendix 4C Cash Flow ReportComments
2026-11-11 · Health care
BB1: $0.590 +3.51% · MC: $106M
BlinkLab reported statistically significant differences in smartphone-based sensory and movement tests between people with a SHANK2 mutation and comparison groups in an exploratory study. The mutation group was small, with fewer than ten participants completing the assessment. Results arrived ahead of the previously expected early next year, while the study does not change the company’s FDA pivotal program for its autism test. BlinkLab expects further exploratory study results before the end of this year.
Updated 2026-11-11 10:22
Sources
Positive Results in Genetic Autism Study Ahead of ScheduleComments
2026-11-09 · Health care
BB1: $0.570 +0.00% · MC: $106M
BlinkLab Limited requested a trading halt pending the release of results from its Shank2 autism study. Trading is expected to resume when the results announcement is released or at the start of normal trading on Wednesday, whichever comes first.
Updated 2026-11-09 09:32
Sources
Trading HaltComments
2026-10-29 · Health care
BB1: $0.625 -0.79% · MC: $106M
BlinkLab reported that its European ADHD study identified 82% of children with ADHD and correctly classified 83% of comparison participants, supporting development of Dx2; the exploratory study is not sufficient for regulatory submission. The company has begun preparing a U.S. pilot study, while its pivotal FDA study for autism product Dx1 remains on track, with completion expected in the current quarter and four research-program readouts expected in the next quarter. BlinkLab held approximately A$16 million in cash at quarter-end.
Updated 2026-10-29 10:36
Sources
Quarterly Activities/Appendix 4C Cash Flow ReportComments
Comments